| Metric | Value ($ M) |
|---|---|
| Revenue | 0.57 |
| Total Income | 0.57 |
| Expenditure | 106.63 |
| PBT | — |
| Net Profit | -107.24 |
| OPM | — |
| NPM | — |
| EPS | -0.81 |
Scholar Rock Reports Q3 2026 Financial Results and Recent Business Highlights
10 Nov 2026 · 2d ago, 5:46 pm
Summary
Scholar Rock Holding Corporation reported its financial results for the third quarter ended September 30, 2026, with a net loss of $107.2 million. The company generated $0.6 million in net product revenue from ISEMBYLD sales in the U.S. during the quarter, marking its first product revenue. Research and development expenses increased to $54.1 million, while SG&A expenses slightly decreased to $52.5 million. The company ended the quarter with $413.6 million in cash, cash equivalents, and marketable securities and announced a definitive agreement to sell a Priority Review Voucher for $205 million.
Key Highlights
- 1
Scholar Rock reported a net loss of $107.2 million for the third quarter ended September 30, 2026.
- 2
The company recorded net product revenue of $0.6 million from sales of ISEMBYLD in the U.S. for the quarter ended September 30, 2026, compared to no revenue in the prior year period.
- 3
Research and development expense was $54.1 million for the quarter ended September 30, 2026, an increase from $50.5 million in the same period of 2025.
- 4
Selling, general and administrative expense was $52.5 million for the quarter ended September 30, 2026, a slight decrease from $53.1 million in the prior year period.
- 5
As of September 30, 2026, Scholar Rock had cash, cash equivalents, and marketable securities of $413.6 million.
- 6
In November 2026, Scholar Rock entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million.
Management Comments
David L. Hallal
The third quarter was a defining period for Scholar Rock, marked by the FDA approval and U.S. launch of ISEMBYLD, the world’s first and only muscle-targeted therapy for children and adults living with SMA. We are very encouraged by the early ISEMBYLD launch dynamics in the U.S., where the breadth of early demand across SMA treatment centers, physicians, and patients reinforces the significant unmet need in the SMA community. With the U.S. launch underway, our regulatory applications advancing in Europe and Japan, important progress across our world-leading anti-myostatin pipeline, and our strengthened financial position, we are building a foundation to redefine the treatment of neuromuscular disease globally and drive sustainable growth for years to come.
Informational and educational content only. Not investment advice.